AstraZeneca PLC or Halozyme Therapeutics, Inc.: Who Leads in Yearly Revenue?

AstraZeneca's Revenue Dominance Over Halozyme: A Decade in Review

__timestampAstraZeneca PLCHalozyme Therapeutics, Inc.
Wednesday, January 1, 20142609500000075334000
Thursday, January 1, 201524708000000135057000
Friday, January 1, 201623002000000146691000
Sunday, January 1, 201722465000000316613000
Monday, January 1, 201822090000000151862000
Tuesday, January 1, 201924384000000195992000
Wednesday, January 1, 202026617000000267594000
Friday, January 1, 202137417000000443310000
Saturday, January 1, 202244351000000660116000
Sunday, January 1, 202345811000000829253000
Monday, January 1, 2024540730000001015324000
Loading chart...

Unleashing the power of data

AstraZeneca vs. Halozyme: A Revenue Showdown

In the competitive landscape of pharmaceuticals, AstraZeneca PLC and Halozyme Therapeutics, Inc. have carved distinct paths. Over the past decade, AstraZeneca has consistently outpaced Halozyme in annual revenue. From 2014 to 2023, AstraZeneca's revenue surged by approximately 76%, reaching a peak in 2023. In contrast, Halozyme's revenue, while growing, remains a fraction of AstraZeneca's, with a notable increase of over 1,000% during the same period. This stark contrast highlights AstraZeneca's dominant market position, driven by its expansive product portfolio and global reach. Meanwhile, Halozyme's growth trajectory, though smaller in scale, underscores its potential in niche markets. As the pharmaceutical industry evolves, these revenue trends offer a glimpse into the strategic directions and market dynamics shaping these two companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025